Dewpoint Therapeutics

Dewpoint Therapeutics is a Boston-based, clinical-stage biotechnology company focused on biomolecular condensates — membraneless organelles formed by phase separation whose behavior is governed by multivalent interactions between proteins and nucleic acids. The company's scientific premise is that dysregulated condensates (which it terms "condensatopathies") drive complex disease through toxic gain of function or loss of function, and that small molecules designed to act on condensates — which it calls condensate modifying drugs, or c-mods — can prevent harmful protein sequestration, drive components back into condensates, and restore normal condensate properties [5].

The company operates an integrated discovery technology it calls ERSA, powered by its AI/ML technology ERSAi, spanning four pillars: target discovery, c-mod discovery, c-mod optimization, and c-mod development. ERSA is supported by an in-house managed proprietary chemical library, proprietary datasets, high-content/high-throughput screening, computer vision and a knowledge graph linking condensates to disease pathology [2][5][6]. Dewpoint states it holds foundational patents, including U.S. Patent 11,340,231 on methods of screening for condensate-associated specificity (May 2022) and U.S. Patent 11,493,519 on characterizing condensate-associated characteristics of compounds (November 2022), plus a 2018 patent application on classifying microscopy images with deep multiple instance learning [5].

Its pipeline includes DPTX3186, a beta-catenin-targeting c-mod in Phase 1/2 for Wnt-pathway-activated solid tumors with a focus on gastric cancer; an oral MYC condensate modulator for solid tumors; a TDP-43 program for ALS and related neurodegenerative diseases; a dilated cardiomyopathy program; and diabetes/insulin-resistance programs. Partnered work includes collaborations with Bayer (cardiovascular), Novo Nordisk (insulin resistance) and Evotec (advancing oncology programs to IND using Evotec's INDiGO platform) [4]. Scientific founders are Anthony (Tony) Hyman and Richard (Rick) Young, with Nobel laureate Phillip Sharp chairing the scientific advisory board; Ameet Nathwani is Chief Executive Officer [2][7].